Sage Journals: Discover world-class research

Abstract

This research was conducted to determine how risk information is presented within direct-to-consumer (DTC) drug advertisements on the World Wide Web (WWW). Twenty prescription drug manufacturers' web sites were examined with respect to risk and benefit information placement. Measured were (a) the number of clicks required to view the benefit and risk information from the home page, (b) the number of clicks to the risk information from the benefit information, (c) the number of clicks to the benefit information from the risk information, (d) and whether scrolling was required to view both benefit and risk information. Also measured were whether the benefit and risk information was on the same page and whether a separate file reader was needed to view the risk information. Results indicated that the risk information is more difficult to find on DTC prescription medication web site advertisements compared to benefits. More clicks from the home page were required to find the risk information than the benefits. Also, scrolling was required more often to find the risk information compared to the benefits. Implications of these results are discussed with respect to the equal balance of risk and benefit information that is required by U.S. Federal Regulations.

Get full access to this article

View all access options for this article.

References

Center for Drug Evaluation and Research (CDER) (2000). Attitudes and behaviors associated with direct-to-consumers (DTC) promotion of prescription drugs. FDA: Office of Medical Policy, Division of Drug Marketing, Advertising and Communications.

Food and Drug Administration (1999). Prescription Drug Advertisements (Federal Register, Title 21 Vol. 4, Parts 200-299). Washington, DC: U. S. Government Printing Office.

Physician's Desk Reference (1999). (53rd Ed). Montvale, NJ: Medical Economics Company, Inc.

Vigilante

W. J.

Jr. (2001). Direct-to-Consumer (DTC) Advertising of Prescription Medications on the World Wide Web: Assessing the Communication of Risk and Benefits. In Proceedings of the Human Factors and Ergnomics Society 45th Annual Meeting. Santa Monica, CA: Human Factors and Ergonomics Society.

Wilkes

M. S.

Bell

R. A.

Kravitz

R.L.

(2000). Direct-to-consumer prescription drug advertising: Trends, impact, and implications Health Affairs, 19, 110–128.

Wogalter

M. S.

Paine

C.S.

Mills

B. J.

Smith-Jackson

T. L.

(1999). Application of cognitive principles to the design of direct-to-consumer advertising of prescription drugs. In Proceedings of the Human Factors and Ergonomics Society 43^rd Annual meeting (pp. 515–519). Santa Monica, CA: Human Factors and Ergonomics Society.

Relative Placement of Benefit and Risk Information in Direct-to-Consumer Advertisements of Prescription Drugs on the World Wide Web

Abstract

Get full access to this article

References